## IAP20 Rec'd PCT/PTO 14 FEB 2006

"Express Mail" mailing label numberEV 393129601 US					
Date of DepositFebr	uary 14, 2006	100-100 V			
I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.  Queen Thomas					
Printed Name	Signature	···			
		PATENT APPLICATION			
IN THE U	NITED STATES PATENT AND	TRADEMARK OFFICE			
Applicants :	HEIMAN, Mark L., et al.	)			
National Phase of PCT Serial No. :	PCT/US2004/025604	) ) )			
International		) )			
Filing Date :	September 2, 2004	ý.			

## INFORMATION DISCLOSURE STATEMENT SUBMITTED SIMULTANEOUSLY WITH NATIONAL PHASE ENTRY

**ANTI-GHRELIN ANTIBODIES** 

X-16339

25885

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

For

Docket No.

Customer No.:

As a means of complying with the duty of disclosure, Applicants submit an "Information Disclosure Citation In An Application" on a Form PTO-1449 (modified) and provide a copy of each of the listed documents for consideration by the Examiner. This form is being submitted simultaneously with the U.S. national phase entry for the above-identified PCT application.

Since this Statement is being filed in accordance with 37 C.F.R. 1.97(b), Applicants submit that no additional fee is required.

Docket No. X16339 International Serial No. PCT/US2004/025604

IAP20 Recide Grando 14 FEB 2006

Applicants request consideration of this information.

Respectfully submitted,

Charles E. Cohen

Attorney for Applicants Registration No. 34,565

Phone: 317-433-4983

Eli Lilly and Company Patent Division P.O. Box 6288 Indianapolis, Indiana 46206-6288

9 February 2006

Sheet 1 of 2

FORM PTO 1449 (modified)			Atty. Docket No. X16339				International Serial No PCT/US2004/025604			
INFORMATION DISCLOSURE CITATION IN AN APPLICATION			First Applicant Mark L. Heiman							
			•	Filing Date US Nat'l Entry (if applicable) Group						
U.S. PAT	FENT	DOCUMENTS							<u>-</u>	· · · · · · · · · · · · · · · · · · ·
Examiner Initials*	Cite No. 1	Document Number  Number-Kind Code <sup>2</sup> (if known)					of Cited Document   When		ges, Columns, Lines, here Relevant Pages or Relevant Figures Appear	
	AA	US								
	AB	US								
	AC	US								
FOREIC	N PA	TENT DOCUMENT	<u>rs</u>					· · · ·		
Examiner Initials*	Cite No. 1	Foreign Patent Document  Country Code <sup>3</sup> -Number <sup>4</sup> - Kind Code5 (if known)		Name of Patentee or Applicant of Cited Publication Date MM-DD-YYYY			Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		T <sup>6</sup>	
	BA	EP 1 197 496		04-17-2002			rigues Appea			
	BB	WO 01/87335	11-22-2001				<u> </u>			
	BC									
NON PATENT LITERATURE DOCUMENTS										
Examiner	Cite	Include name of the author	(in CAPIT	TAL LETTERS).	title of the a	rticle (whe	en appre	opriate), title of t	he item	т6
Initials*	No. 1	(book, magazine, journal, se	(book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s) publisher, city and/or country where published.							
	CA	International Search R	International Search Report							
	СВ	ARIYASU, et al., "Stomach is a major source of circulating ghrelin, and feeding state determines plasma ghrelin-like immunoreactivity levels in humans," <u>Journal of Clinical Endocrinology &amp; Metabolism</u> , vol. 86, no. 10, October 2001, pp. 4753-4758.								
	CC	DATABASE Genesed light chain variable reg	DATABASE Geneseq Online, August 13, 2001, "Murine anti-Pl-3, 4-P2 antibody light chain variable region," XP002322695.							
	CD	DATABASE Geneseq Online, August 13, 2001, "Murine anti-PI-3, 4-P2 lg light chain CDR1," XP002322696.								
	CE	CE HOLT, et al., "Domain antibodies: proteins for therapy," <u>Trends in Biotechnology</u> , vol 21, no. 11, November 2003, pp. 484-490.								
Examiner Signature					Date Cons	idered				

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached. Burden Hours Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to their Information Officer. U.S. Patent and Trademark Office. Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

## JAP20 Rec'd PGT/PTO 14 FEB 2006,

Sheet 2 of 2

FORM PTO 1449 (modified)			Atty. Docket No. X16339	International Serial No PCT/US2004/025604 In / 568467		
INFORMATION DISCLOSURE CITATION IN AN APPLICATION			First Applicant Mark L. Heiman	80170040F		
			Filing Date US Nat'l Entry (if applicable)	Group		
NON PATE	ENT I	LITERATURE DOCUM	ENTS (cont.)	-		
· C	CF	HOSODA, et al., "Ghrelin and des-acyl ghrelin: Two major forms of rat ghrelin peptide in gastrointestinal tissue," <u>Biochemical and Biophysical Research</u> Communications, vol. 279, no. 3, December 29, 2000, pp. 909-913.				
C	CG	MURAKAMI, N., et al., "Role for central ghrelin in food intake and secretion profile of stomach ghrelin in rats, <u>Journal of Endocrinology</u> , vol. 174, no. 2, August 2002, pp. 283-288				
C	CH					

Examiner	Date Considered	
Signature		

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901,04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached. Burden Hours Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer. U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.